Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Brain and Central Nervous System Tumors
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Enrollment
- 80
- Locations
- 1
- Primary Endpoint
- Changes in thymidine kinase, thymidylate synthase, and standardized uptake values
- Status
- Recruiting
- Last Updated
- 9 months ago
Overview
Brief Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Detailed Description
OBJECTIVES: Primary * Evaluate the use of 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer. Secondary * Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment. OUTLINE: Patients undergo up to four 3'-deoxy-3'-\[18F\] fluorothymidine positron emission tomography imaging procedures.
Investigators
Anthony F. Shields, MD PhD
Principal Investigator
Barbara Ann Karmanos Cancer Institute
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Changes in thymidine kinase, thymidylate synthase, and standardized uptake values
Time Frame: before and after therapy
Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs
Time Frame: at time of PET or CT PET Scan
Secondary Outcomes
- FLT PET response rate(up to 2 hours during PET scan)